Posted by Michael Wonder on 02 Nov 2022
Department tweaks the agenda for the Nov 2022 PBAC meeting yet again
2 November 2022 - Two changes made on the eve of the meeting.
The submissions for acalabrutinib (Calquence) and ibrutinib (Imbruvica) will be considered at a future PBAC meeting.
